Effect of XELOX on functional ability among elderly patients with metastatic colorectal cancer: Results from the FNCLCC/GERICO 02 phase II study

Frédérique Rousseau, Roland Bugat, Michel Ducreux, Frédérique Cvitkovic, Elisabeth Carola, Mathilde Gisselbrecht, Frédéric Viret, Benjamin Esterni, Jean Genève, Etienne Brain

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    3 Citations (Scopus)

    Résumé

    Objectives: This study investigated the effect of capecitabine-oxaliplatin (XELOX) on functional independence in patients aged ≥ 70 years with histologically proven metastatic colorectal cancer (mCRC). Materials and methods: Patients received capecitabine 750mg/m2 bid d1-14+oxaliplatin 90mg/m2 d1, every 3weeks; doses were increased to 1000 and 120mg/m2, respectively, in the absence of significant toxicity. The primary endpoint was stabilization/improvement of Katz Activities of Daily Living (ADL) scale. Results: Sixty patients were enrolled. ADL was stabilized/improved in 36/40 patients (90%) after 3. cycles, and in 25/27 patients (93%) after 6. cycles. Capecitabine and oxaliplatin doses were increased in 31% of patients. The objective response rate was 37% (1 complete and 21 partial responses). Toxicity included grade 3/4 diarrhea (13%), neurotoxicity (grade 1/2 in 68%, grade 3/4 in 2%), and grade 3/4 anemia (7%). Conclusion: This study demonstrates the feasibility of XELOX in elderly mCRC patients, with no impairment of independence among patients who remained on therapy.

    langue originaleAnglais
    Pages (de - à)105-111
    Nombre de pages7
    journalJournal of Geriatric Oncology
    Volume2
    Numéro de publication2
    Les DOIs
    étatPublié - 1 avr. 2011

    Contient cette citation